Related Experiment Video
Updated: Jun 15, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Atrial fibrillation and platelet reactivity
M Milovanovic1, E Fransson1, C Hallert1
1Department of Internal Medicine, the Vrinnevi Hospital, Norrköping, Sweden.
International Journal of Cardiology
|March 19, 2010
Summary
Atrial fibrillation (AF) patients showed altered platelet reactivity post-cardioversion. Those remaining in sinus rhythm (SR) had lower reactivity, while those reverting to AF exhibited higher reactivity after 26 months.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Clinical Research
Background:
- The relationship between atrial fibrillation (AF) and platelet reactivity remains under-explored.
- Investigating platelet function in AF patients is crucial for understanding thrombotic risk.
Purpose of the Study:
- To assess the impact of electrical cardioversion (ECV) on platelet reactivity in patients with atrial fibrillation.
- To compare platelet reactivity in patients who maintained sinus rhythm versus those who reverted to AF post-ECV.
Main Methods:
- 33 AF patients underwent ECV; platelet reactivity was measured using flow cytometry with ADP and thrombin receptor activating peptide agonists.
- Measurements were taken immediately before ECV and repeated after an average of 26 months.
- Platelet surface-bound fibrinogen was determined as an indicator of platelet activation.
Main Results:
- At 26 months, patients who reverted to AF (n=18) showed a trend towards lower platelet reactivity compared to baseline, significant with 1.7 μmol/L ADP.
- Patients who maintained sinus rhythm (SR) (n=15) exhibited significantly lower platelet reactivity with all agonists at 26 months.
- Crucially, patients with recurrent AF at follow-up had higher platelet reactivity than those in SR.
Conclusions:
- Long-term sinus rhythm following cardioversion is associated with reduced platelet reactivity.
- Recurrent atrial fibrillation after cardioversion is linked to increased platelet reactivity, suggesting a higher thrombotic risk.
Related Concept Videos
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...